BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy

Abstract Clinical trials are currently exploring combinations of PARP inhibitors and immunotherapies for the treatment of ovarian cancer, but their effects on the ovarian tumour microenvironment (TME) remain unclear. Here, we investigate how olaparib, PD-L1 monoclonal antibodies, and their combinati...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Salar Farokhi Boroujeni, Galaxia Rodriguez, Kristianne Galpin, Edward Yakubovich, Humaira Murshed, Dalia Ibrahim, Sara Asif, Barbara C. Vanderhyden
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2023-11-01
Edice:	Journal of Ovarian Research
Témata:	BRCA mutations Ovarian cancer PARP inhibitors Immune checkpoint inhibitors
On-line přístup:	https://doi.org/10.1186/s13048-023-01313-z
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!